Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Emma Jo Hayton"'
Autor:
Julian Bion, Olivia Brookes, Celia Brown, Carolyn Tarrant, Julian Archer, Duncan Buckley, Lisa-Marie Buckley, Ian Clement, Felicity Evison, Fang Gao Smith, Chris Gibbins, Emma-Jo Hayton, Jennifer Jones, Richard Lilford, Randeep Mullhi, Greg Packer, Gavin D Perkins, Jonathan Shelton, Catherine Snelson, Paul Sullivan, Ivo Vlaev, Daniel Wolstenholme, Stephen Wright, the PEARL collaboration
Publikováno v:
Health Services and Delivery Research, Vol 8, Iss 32 (2020)
Background: Although most health care is high quality, many patients and members of staff can recall episodes of a lack of empathy, respect or effective communication from health-care staff. In extreme form, this contributes to high-profile organisat
Externí odkaz:
https://doaj.org/article/8ef0484f02184608adc480a055894ec2
Autor:
Emma-Jo Hayton, Annie Rose, Umar Ibrahimsa, Mariarosaria Del Sorbo, Stefania Capone, Alison Crook, Antony P Black, Lucy Dorrell, Tomáš Hanke
Publikováno v:
PLoS ONE, Vol 9, Iss 7, p e101591 (2014)
HIV-1 vaccine development has advanced slowly due to viral antigenic diversity, poor immunogenicity and recently, safety concerns associated with human adenovirus serotype-5 vectors. To tackle HIV-1 variation, we designed a unique T-cell immunogen HI
Externí odkaz:
https://doaj.org/article/4f155129a22b4f1d997e36865162901c
Autor:
Adrian V. S. Hill, Jill Gilmour, Peter Hayes, Lucy Dorrell, Nicola Borthwick, Umar Ebrahimsa, A P Black, Andrew J. McMichael, Maximillian Rosario, Anne Bridgeman, Eleanor Berrie, Beatrice Ondondo, A Rose, Nicole Frahm, Emma Jo Hayton, Tomáš Hanke, Stefano Colloca, Josephine H. Cox, Alfredo Nicosia, T Ahmed, Sarah Moyle
Virus diversity and escape from immune responses are the biggest challenges to the development of an effective vaccine against HIV-1. We hypothesized that T-cell vaccines targeting the most conserved regions of the HIV-1 proteome, which are common to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ef91be46e4d25a6e9090d33a17bb81f
https://ora.ox.ac.uk/objects/uuid:3e4bd652-28c3-45ee-b404-6946fda6d996
https://ora.ox.ac.uk/objects/uuid:3e4bd652-28c3-45ee-b404-6946fda6d996
Autor:
Oliver O Koch, Ian C. J. W. Bowler, Francis Drobniewski, Nikant Sabharwal, Matthew Scarborough, Emma-Jo Hayton
Publikováno v:
JMM Case Reports. 2
Introduction We present a case of pacemaker infection with a rapidly growing mycobacterium (RGM). Case presentation: An 80-year-old woman presented with fever, weight loss and malaise for 2 months. Mycobacterium neoaurum was isolated from blood cultu
Autor:
Tomáš Hanke, A Rose, Lucy Dorrell, Mariarosaria Del Sorbo, Stefania Capone, Alison Crook, A P Black, Umar Ibrahimsa, Emma-Jo Hayton
Publikováno v:
PLoS ONE
PLoS ONE, Vol 9, Iss 7, p e101591 (2014)
PLoS ONE, Vol 9, Iss 7, p e101591 (2014)
Trial Design HIV-1 vaccine development has advanced slowly due to viral antigenic diversity, poor immunogenicity and recently, safety concerns associated with human adenovirus serotype-5 vectors. To tackle HIV-1 variation, we designed a unique T-cell
Autor:
Andrew J. McMichael, Nicola Borthwick, Hongbing Yang, U Ebrahimsa, Emma-Jo Hayton, Nicole Frahm, Gemma Hancock, A P Black, Alfredo Nicosia, Lucy Dorrell, A Rose, T Ahmed, Suzanne Campion, Tomáš Hanke, Stefano Colloca
Publikováno v:
Retrovirology
Retrovirology, Vol 9, Iss Suppl 2, p P118 (2012)
Retrovirology, Vol 9, Iss Suppl 2, p P118 (2012)
Background The major challenge facing both antibody and T celleliciting vaccines against HIV-1 is the extreme variability of the HIV-1 genome: a successful vaccine has to effectively target diverse HIV-1 strains circulating in the population and then
Autor:
Nicola Borthwick, L Yorke, T Ahmed, Andrew J. McMichael, Lucy Dorrell, Hongbing Yang, Tomáš Hanke, A Rose, A P Black, U Ebrahimsa, Emma-Jo Hayton, Gemma Hancock
Publikováno v:
Retrovirology
Retrovirology, Vol 9, Iss Suppl 2, p P259 (2012)
Retrovirology, Vol 9, Iss Suppl 2, p P259 (2012)
Results HIV-1 infection kinetics is influenced by the multiplicity of infection (MOI) used to infect autologous CD4+ cells, with rapid kinetics observed at higher MOIs. For HIV-1 BaL optimal infection of autologous CD4+ cells was achieved at MOI of 0